Vir Biotechnology Inc V.VIR

Primary Symbol: VIR

Healthcare Biotechnology

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

NDAQ:VIR - Post by User

Vir Biotechnology Inc > Open bids already starting to build on Pot stock/Lab merger

<< Previous

Bullboard Posts

Next >>

Comment by Amalfi1on Feb 12, 2019 11:29am

57 Views

Post# 29352915

RE:RE:RE:Open bids already starting to build on Pot stock/Lab merger

Why do you say it’s a scam? Do you think a licensed company (on the TSVX, and not the “unregulated” CSE), with every license Health Canada can issue...(go to the HC website, and you will see Experion has the “Sales, Processing, and Cultivation Licenses”) and also with the potential of getting one of the coveted German licenses next month when Germany announces who will receive one of licenses Germany will issue.

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price